In a powerful move, Kenneth Frazier, CEO at Merck, resigned today from the American Manufacturing Council led by the Trump administration. In a public statement shared via Merck’s Twitter account, he said:Read More
Americans are on pins and needles as the Senate reviews the American Health Care Act. While we are unsure of what the final bill will look like, many are worried it could result in millions of Americans losing their health insurance.Read More
Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the body’s immune system to detect and fight cancer. Researchers have coined immunotherapy as the “beginning to the end of cancer” and we continue to see the space flourish.
I had the great privilege of speaking with Cheddar about the importance of cancer immunotherapy and OncoSec's role in the fight to end cancer. We discuss the advantages of intratumoral therapy, the future of cancer care, and how OncoSec is positioned to solve a great unmet need in oncology. Check out the full interview for more!Read More
This week, President Donald Trump unveiled his new executive order on immigration to respond to recent court rulings. As you may know, federal judges put a hold on the President’s original executive order that banned immigrants from seven majority-Muslim countries to enter the US.
In December, the healthcare industry rejoiced as the 21st Century Cures Act achieved overwhelming bipartisan support in Congress and was signed into law by Former President Obama. The new legislation aims to increase funding for cancer research, speed the development and approval of new treatments, and strengthen mental health services.Read More
There are thousands of do-it-yourself seminars, books, and articles to help entrepreneurs achieve success. Business leaders continually look for the latest advancements and insights into what can make their company great. But sometimes the answer can be right underneath your nose, and it’s one of the most inherent, yet commonly overlooked aspects of a company.Read More
News of the United States’ 39th President Jimmy Carter and his recent diagnosis of advanced melanoma has left many of us introspective. We are taking time to reflect on the epidemic that is cancer, which affects the famous and the not-so-famous indiscriminately and all too often.Read More
We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market.Read More
As June marks Cancer Immunotherapy Awareness Month, I wanted to reflect on some of the key scientific takeaways from the American Society of Clinical Oncology’s (ASCO) annual meeting, and how these advancements are shaping the future of immunotherapy and our work at OncoSec.Read More
Looking ahead, our work is cut out for us in terms of R&D as many diseases and conditions are yet to be fully understood. By establishing partnerships with academia, we can further explore disease states, concentrate on early-stage molecule development, and optimize a product candidateRead More
As we move into the Process Innovation era, new ways of developing more effective and safer treatments are required. In 2010, the number of drug approvals hit a record low, and several high profile molecules that had shown promise failed in the late stage of developmentRead More
Today, the pharma landscape is increasingly multifaceted, but it’s taken us a while to reach this moment in time. Fifteen years ago, the pharma landscape was centered on Product Performance: discovering or synthesizing molecules that deliver proven clinical results. Under this principle, sales reps marketed to and dealt directly with physicians, and there was little communication with or educational resources for consumers.Read More
Yesterday afternoon, the FDA granted accelerated approval to Merck’s anti-PD1 drug Keytruda, formerly known as MK-3475, for advanced or unresectable melanoma no longer responding to current therapies. I applaud the FDA’s swift approval, and believe that this decision marks a great turning point for immuno-oncology.Read More
My family and close friends know how fanatical I can be about the Grouse Grind – simply if Vancouver could embody a prototypical stereotype, the “Grind” as more commonly referred to would be up there with running around Stanley Park in your Lululemon outfit.
Last month, the Chair of the Federal Reserve, Janet Yellen, made headline news when she weighed in on stock valuations in her semiannual monetary policy report. In her testimony before the Senate Banking Committee, Dr. Yellen made the following statement:
In the December 2013 issue of Science, Cancer immunotherapy was named as the Breakthrough of the Year. My initial reaction to this was a little shocking and wondering what finally swayed the sceptics to realize this? Internally, we have been calling it a breakthrough for sometime, what did we mean by calling it a breakthrough in the first place?Read More
One in five individuals is likely to suffer from skin cancer at some point in their lives, and the numbers are steadily increasing. Despite advances that have been made in sunscreen technology and growing public awareness of the need for sunscreen...Read More